Contract extension to further boost WhiteHawk’s rapid revenue growth

|

Published 06-OCT-2020 10:23 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

WhiteHawk Limited (ASX:WHK), the first global online cyber security exchange enabling small-to-medium businesses to take smart action against cybercrime, fraud and disruption, has been awarded a fiscal 2021 option extension of US$1.5 million (A$2.1M) under an existing 7 year contract.

As previously noted, the contract with a US Federal government Department was for a 1 year contract with 6 option years, and WhiteHawk has been advised that the option for the next financial year has now been exercised, which is worth US$1.5 million to the company over the 2021 financial year.

Reflecting WhiteHawk's capabilities, the US$1.5 million extension is an increase on the US$400,000 in revenue awarded to the company under the contract for the 2020 financial year.

The focus of this contract for WhiteHawk has evolved from cyber risk technical and management services, scoped at US$400,000 to US$750,000 per year, to now lead developer of a comprehensive online Cyber Security Marketplace, with an automated cyber risk review and solution option mapping, for a breadth of US Federal Government entities.

This is an important development for WhiteHawk as revenues across the group are rapidly ramping up, having more than doubled to approximately US$585,000 in the first half of 2020.

On an annualised basis, this was broadly in line with the company’s revenues for 2019 which were just above US$1 million.

Consequently, on a year-on-year basis this contract alone represents about 150% of the previous year’s revenues.

Paves the way for further government option year contract extensions

From an operational perspective, the award underlines WhiteHawk's product capability and service level execution to perform on all current contracts to achieve further government option year contract extensions and to engage with future customers seamlessly and effectively throughout the current global pandemic.

It is worth noting that this comes just a fortnight after the company announced the automation and scaling of two key product lines, the Cyber Risk Scorecard and CMMC that were added to the online maturity model, enabling scalability across thousands of companies, an added attraction for organisations looking to extend contracts.

Terry Roberts, Executive Chair of WhiteHawk, highlighted the benefits of the group’s real-time, end- to-end automated product offerings in saying, “We are discovering that our unique end-to-end automated approach to identifying, prioritising and mitigating cyber risks via an easily assessable online platform is increasingly attractive to both government and industry alike as it provides near real-time servicing of their stakeholder organisations or clients.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X